EGFR-Mutated NSCLC: Risk–Benefit Assessment in First-Line Treatment Decisions

In this segment, Dr. Sands leads a discussion on how clinicians approach risk–benefit assessment in EGFR-mutated non-small cell lung cancer as newer combination strategies become available. He first shares his perspective, emphasizing the importance of individualizing treatment decisions based on patient characteristics, disease biology, and patient preferences. Dr. Wakelee and Dr. Cooper build on this by describing how clinicians weigh efficacy outcomes alongside toxicity profiles, recognizing that median trial results do not fully capture the variability in individual patient responses. They highlight the need to consider both short-term benefits, such as response rates, and long-term outcomes, including durability of response and overall survival. The panel also discusses the importance of clearly communicating potential toxicities without oversimplification, noting that patient perception of side effects can significantly influence decision-making. Overall, the discussion underscores that risk–benefit assessment in EGFR-mutated NSCLC is highly nuanced and requires a personalized, patient-centered approach.